Breadcrumb other pages

ERINHA-Advance first TransNational Access Call

Through the EU funded H2020 project ERINHA-Advance, we are now opening our first call for proposals to offer scientists free of charge* transnational access (TNA) to ERINHA’s full catalog of services, including access to cutting edge high containment facilities.
* Free of charge transnational access includes administrative & logistical support, free use of the installations, in accordance with all applicable national laws, local safety and health regulations, and technical and scientific support. It does not include any other costs (travel and/or subsistence costs; consumables; animals; etc…).

ERINHA AISBL has aligned its scientific strategy with the WHO Blueprint list of priority diseases and will therefore prioritize applications related to the following pathogens:

  • Ebola virus
  • Marburg virus
  • Lassa virus
  • Crimean-Congo Hemorrhagic Fever virus
  • Nipah virus

In addition, applications must fall into one of the following scientific topics:

SECTION 1: Innovative therapeutics, vaccines or diagnosis approaches for RG4 pathogens

  • Development of RG4 pathogens’ standards for diagnosis
  • Development of innovative technologies for diagnosis
  • Development of innovative alternatives for antibodies production for diagnosis and therapeutics purpose
  • Development of innovative therapeutics tools/ immunotherapy
  • Development of new synthetic methods to improve immunogenicity of vaccines
  • Development of new approach for the design of antiviral drugs
  • Development of vaccines against RG4 pathogens

SECTION 2: Innovative approaches to study highly infectious viruses in animal experimentation

  • Optimization/ adaptation of rodent models
  • Development of telemetry technics/ biochemistry technics for animal experimentation
  • Development and optimization of alternative technologies to animal models
  • Development of innovative real-time imaging capacity in BSL-4 conditions

If you are currently working on a project that meets the above requirements, this is a unique opportunity to avail of ERINHA services and expertise, and:

  • Perform a final step of validation
  • Perform a preliminary study
  • Adapt methods & approaches to highly pathogenic viruses

For more information about our TNA Programme, including the conditions for access & eligibility, and the selection process, please see our TNA Guidelines, or contact our staff at the Central Coordinating Unit

To participate in the call, please download the following documents:


Opening of the call: 15 October 2019
Submission deadline: 15 December 2019
Evaluation and Selection deadline: February 2020
Feedback to applicants: March 2020

ERINHA Advance has partnered with TRANSVAC2, a collaborative infrastructure project funded by the European Commission and coordinated by the European Vaccine Initiative (EVI). TRANSVAC2 is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of vaccine projects by implementing a permanent research infrastructure. ERINHA Advance’s 1st TNA call and TRANSVAC’s 7th call for proposals have been launched simultaneously. Applicants with interest in highly pathogenic agents and vaccine development are encouraged to apply to both calls.
For more information on TRANSVAC’s current call for TNA services, please go to